Edited by George N. DeMartinoCullin-RING ligase 4 (CRL4), a complex of Cul4 and DDB1, regulates the cell cycle, DNA damage repair, and chromatin replication by targeting a variety of substrates for ubiquitination. CRL4 is also hijacked by viral proteins or thalidomide-derived compounds to degrade host restriction factors. Here we report that the c-Abl non-receptor kinase phosphorylates DDB1 at residue Tyr-316 to recruit a small regulatory protein, DDA1, leading to increased substrate ubiquitination. Pharmacological inhibition or genetic ablation of the Abl-DDB1-DDA1 axis decreases the ubiquitination of CRL4 substrates, including IKZF1 and IKZF3, in lenalidomide-treated multiple myeloma cells. Importantly, panobinostat, a recently approved anti-myeloma drug, and dexamethasone enhance lenalidomide-induced substrate degradation and cytotoxicity by activating c-Abl, therefore providing a mechanism underlying their combination with lenalidomide to treat multiple myeloma.The cullin-RING ubiquitin ligases (CRLs), 2 comprising the scaffold cullins, the E2-interacting RING finger protein ROC1/2, the adaptor proteins specific for each cullin family member, and adaptor-interacting substrate receptors, are the largest family of E3 ligases in eukaryotes, regulating diverse cellular pathways (1). CRL4 uses the damaged DNA binding protein 1 (DDB1) as the adaptor protein to assemble with a subset of WD40-containing proteins called DDB1-and Cullin4 (Cul4)-associated factors to target diverse substrates to regulate the cell cycle, DNA damage repair, and chromatin functions (1-3). CRL4 ubiquitinates cellular proteins such as CDT1 (4), P21 (5, 6), and DDB2 (7) for proteasomal degradation and teneleven translocation (TET) proteins (8) and histones H2A (9), H3 (10, 11), and H4 (10) to regulate their chromatin-mediated functions. Several viral proteins can hijack CRL4 to turn over host restriction factors to promote virus replication, including STAT1 targeted by SV5 virus V protein (12-14), SAMHD1 by simian HIV Vpr protein (15), and Smc5/6 by hepatitis B virus X protein (16).Additionally, immunomodulatory drugs (IMiDs), including thalidomide and its derivatives lenalidomide and pomalidomide, can repurpose CRL4 to target and destroy IKZF1 and IKZF3 (17, 18), two lymphoid transcription factors essential for multiple myeloma (MM) cell survival. Similarly, lenalidomide induces ubiquitination and degradation of casein kinase 1A1 (CK1␣), which accounts for the clinical efficacy of lenalidomide in myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)) (19). Crystal structure studies reveal that the glutarimide moiety of lenalidomide directly inserts into a hydrophobic pocket of cereblon (CRBN), a CRL4 substrate receptor, and that the exposed chemical moiety, together with CRBN, creates a new surface for receiving substrates (20 -22). Based on these results, novel chemicals conjugating glutarimide to other protein-interacting chemical structures are designed to control protein stability and thus enable targeting of previously...